Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05661201Phase 1Recruiting

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Role: collaborator

NCT04365179Phase 1Recruiting

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Role: lead

NCT03634150Phase 1Withdrawn

Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Role: lead

NCT03059615Phase 2Withdrawn

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

Role: lead

NCT01690741Phase 1Completed

Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies

Role: lead

All 5 trials loaded